FDA denial of anticancer drug spurs lawsuit.
A group of disappointed patients and disgruntled investors is suing Food and Drug Administration (FDA) officials over the agency's decision to nix a proposed vaccine Provenge [R] for advanced prostate cancer. *
The July 30 federal lawsuit, filed by the non-profit Care to Live, claims Provenge [R] is safe and effective and that the FDA's decision was the result of political infighting. It also accuses the agency of ignoring conflict-of-interest issues, naming Dr. Howard Scher, a leading investigator of a competitor anticancer drug and one of the advisors who reviewed the Provenge [R] data.
The FDA's denial in May of this year followed a thumbs-up from its own advisory panel two months earlier. Provenge [R] developer Dendreon, Inc. is hoping to win approval after a larger trial.
* Available at: http://seattletimes.nwsource.com/html/ businesstechnology/2003813806_dendreon31.html. Accessed August 13, 2007.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||In The NEWS; Food and Drug Administration|
|Article Type:||Brief article|
|Date:||Nov 1, 2007|
|Previous Article:||Vitamin C may protect against arthritic changes in the knees.|
|Next Article:||Coenzyme Q10 improves endothelial function.|
|It's the 'Fast Track' for a new cancer drug.|
|IL-12 studies back on track.|
|Claim based on deceptive drug ads is preempted, Third Circuit holds.|